Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T ₁ − T ₂ W MR Imaging of MDA-MB-231

) than commercial contrast agents (MAGNEVIST, GADOVIST, PROHANCE, etc.), indicating its potency as a dual-mode contrast agent for magnetic resonance imaging (MRI). We have also validated a drug co-loading mechanism through a series of molecular dynamics simulations, followed by experimental measurements. Importantly, in vivo studies using a xenograft mouse model demonstrate significant tumor growth inhibition, with the nanoformulation + NIR irradiated group showing the most effective anti-tumor outcome with negligible hepatic, renal, and cardiac toxicities. Taken together, it may be stated that the doxorubicin/JQ1 co-loaded PBNCs might be a potential next-generation anti-TNBC theranostic agent, which combines dual-mode MRI capability and combination therapy with reduced side effects.